Maximizing T-cell memory and compositions and methods therefor

US11229668B2 · kind B2 · utility

Assignees

• NantCell, Inc. · US
• Nant Holdings IP, LLC · US

Inventors

• Shahrooz Rabizadeh · Culver City, US
• Kayvan Niazi · Los Angeles, US
• Patrick Soon-Shiong · Los Angeles, US
• Hing C. Wong · San Ramon, US
• Wenxin Xu · Culver City, US

Key dates

• Filing date: Feb 8, 2018
• Grant date: Jan 25, 2022
• Expiry date: Feb 8, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/86
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.